Prof. Teresa Quattrin

State University of New York, USA

Email: tquattrin@upa.chob.edu

Qualifications

1982  M.D., University of Naples, Italy

Publications (Selected)

1. Stone AT, Quattrin T: Higher BMI and Dental Decay May Be Linked. The Endocrine Society’s 92th Annual Meeting, San Diego CA, June 19-22, 2010.
2. Rafalson L, Eysaman J, Meeks G, Golubski J, Butler S, Donahue RP, Quattrin T: Screening overweight school-aged students at high risk for impaired glucose metabolism in the Buffalo public schools.  8th Joint Meeting of the LWPES/ESPE, Global Care in Pediatric Endocrinology, New York, NY, September 9 –12, 2009.
3. Mastrandrea LD, Yu J,  Behrens T, Buchlis J, Albini C,  Fourtner S, Quattrin T: Randomized Placebo Based Double Blind Study Evaluating the Feasibility and Safety of Etanercept to Prolong the Partial Remission Period in Type 1 Diabetes Mellitus. Diabetes Care 32: 1244-1249, 2009.
4. Quattrin, T: Etanercept Treatment in Children with New-Onset Type 1 Diabetes: Response to Peters.  Diabetes Care, 32:12, 2009.
5. Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T: Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 31:1729-1735, 2008.
6. Cappelleri JC, Gerber RA, Quattrin T, Deutschmann R, Luo X, Arbuckle R, Abetz L: Assessment of Parents’ Quality of Life and Satisfaction with their Child’s Treatment for Diabetes: Development and Validation of the WEll-being and Satisfaction of CAREgivers of Children with Diabetes Questionnaire (WE-CARE). Health and Quality of Life Outcomes 6:3, January 2008.
7. White NH, Quattrin T, St Aubin LB, Duggan WT, England RD, Fryburg JS: Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial. Journal of Pediatric Endocrinol Metab 21:555-568, 2008.
8. Daniel M, Quattrin T: Dopamine receptor genotyping in children with short stature treated with growth hormone therapy. The Endocrine Society’s 90th Annual Meeting, San Francisco CA, June 15-18, 2008.
9. Danilovich N, Quattrin T: Do insulin or dopamine affect energy intake? The Endocrine Society’s 90th Annual Meeting, San Francisco CA, June 15-18, 2008.
10. Mastrandrea L and Quattrin, T: Clinical Evaluation of Inhaled Insulin. Advanced Drug Delivery Reviews (58):1061-1075, 2006.
11. Quattrin, T: Inhaled Insulin: a novel and non-invasive way for insulin administration. Current Drug Safety, Bentham Publisher, 1 (2):151-158, 2006.
12. Quattrin, T: Intensive Insulin Therapy – Present and Future.  Business Briefing: US Pediatric Care, p. 43-45, 2005.
13. Quattrin, T: Childhood Obesity: Benefits of lifestyle-modification therapy.  Pediatrics 116:292-293, 2005.
14. Review for “Obesity in Childhood and Adolescence” by W. Kleiss, C. Marcus and M Wabitsch. Karger 2004: Quattrin, T: Current knowledge and future directions in the complex field of pediatric overweight. Trends in Endocrinology and Metabolism, 16 (10): 443-444, 2005.
15. Quattrin T: Inhaled insulin: recent advances in the therapy of type 1 and type 2 diabetes. Expert Opinion Pharmacotherapy (12):2597-2604, 2004.